Caseware UK (AP4) 2024.0.164 2024.0.164 2024-12-312024-12-31No description of principal activity2024-01-01false108truetrueThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.false 10244199 2024-01-01 2024-12-31 10244199 2023-01-01 2023-12-31 10244199 2024-12-31 10244199 2023-12-31 10244199 c:Director1 2024-01-01 2024-12-31 10244199 c:RegisteredOffice 2024-01-01 2024-12-31 10244199 d:Buildings d:LongLeaseholdAssets 2024-01-01 2024-12-31 10244199 d:Buildings d:LongLeaseholdAssets 2024-12-31 10244199 d:Buildings d:LongLeaseholdAssets 2023-12-31 10244199 d:PlantMachinery 2024-01-01 2024-12-31 10244199 d:FurnitureFittings 2024-01-01 2024-12-31 10244199 d:FurnitureFittings 2024-12-31 10244199 d:FurnitureFittings 2023-12-31 10244199 d:FurnitureFittings d:OwnedOrFreeholdAssets 2024-01-01 2024-12-31 10244199 d:OwnedOrFreeholdAssets 2024-01-01 2024-12-31 10244199 d:CurrentFinancialInstruments 2024-12-31 10244199 d:CurrentFinancialInstruments 2023-12-31 10244199 d:Non-currentFinancialInstruments 2024-12-31 10244199 d:Non-currentFinancialInstruments 2023-12-31 10244199 d:CurrentFinancialInstruments d:WithinOneYear 2024-12-31 10244199 d:CurrentFinancialInstruments d:WithinOneYear 2023-12-31 10244199 d:ShareCapital 2024-12-31 10244199 d:ShareCapital 2023-12-31 10244199 d:RetainedEarningsAccumulatedLosses 2024-12-31 10244199 d:RetainedEarningsAccumulatedLosses 2023-12-31 10244199 c:FRS102 2024-01-01 2024-12-31 10244199 c:AuditExempt-NoAccountantsReport 2024-01-01 2024-12-31 10244199 c:FullAccounts 2024-01-01 2024-12-31 10244199 c:PrivateLimitedCompanyLtd 2024-01-01 2024-12-31 10244199 e:PoundSterling 2024-01-01 2024-12-31 iso4217:GBP xbrli:pure
Registered number: 10244199 (England & Wales)



 






LONDON HORMONE CLINIC LIMITED


DIRECTORS' REPORT AND UNAUDITED FINANCIAL STATEMENTS


FOR THE YEAR ENDED 
31 DECEMBER 2024





Pages for Filing with Registrar


























 
LONDON HORMONE CLINIC LIMITED
 

CONTENTS



Page
Company Information
 
1
Balance Sheet
 
2 - 3
Notes to the Financial Statements
 
4 - 8



 
LONDON HORMONE CLINIC LIMITED
 
 
COMPANY INFORMATION


Director
Janine Toledano 




Registered number
10244199



Registered office
40 Queen Anne Street

London

W1G 9EL




Accountants
Lewis Golden LLP

40 Queen Anne Street

London

W1G 9EL




1 -


 
Registered number: 10244199 (England & Wales)
LONDON HORMONE CLINIC LIMITED


BALANCE SHEET
AS AT 31 DECEMBER 2024

2024
2023
Note
£
£

Fixed assets
  

Tangible assets
 4 
141,476
154,849

Current assets
  

Debtors: amounts falling due after more than one year
 5 
-
4,386

Debtors
 5 
121,348
98,368

Cash at bank and in hand
  
129,271
52,314

  
250,619
155,068

Creditors: amounts falling due within one year
 6 
(289,180)
(226,182)

Net current liabilities
  
 
 
(38,561)
 
 
(71,114)

Provisions for liabilities
  

Deferred tax
  
(8,372)
-

  
 
 
(8,372)
 
 
-

Net assets
  
94,543
83,735


Capital and reserves
  

Called up share capital 
  
1,000
1,000

Profit and loss account
  
93,543
82,735

  
94,543
83,735


2 -


 
Registered number: 10244199 (England & Wales)
LONDON HORMONE CLINIC LIMITED

    
BALANCE SHEET (CONTINUED)
AS AT 31 DECEMBER 2024

The director considers that the company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The director acknowledges her responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The company has opted not to file the Director's Report and Profit and Loss Account in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the director




................................................
Janine Toledano
Director

Date: 14 September 2025

The notes on pages 4 to 8 form part of these financial statements.

3 -


 
LONDON HORMONE CLINIC LIMITED
 
 

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

1.


General information

London Hormone Clinic Limited is a private company limited by share capital, incorporated in England and Wales, registered number 10244199. The address of the registered office is 40 Queen Anne Street, London W1G 9EL. 

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Section 1A - small entities of Financial Reporting Standard 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' ('FRS 102') and the Companies Act 2006.

The following principal accounting policies have been applied:

  
2.2

Going concern

The financial statements have been prepared on a going concern basis, as the company intends to continue to provide services throughout the post year end period.

 
2.3

Turnover

Turnover is recognised to the extent that it is probable that the economic benefits will flow to the company and the turnover can be reliably measured. Turnover is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before turnover is recognised:

Rendering of services

Turnover from the rendering of services is recognised in the period in which the services are provided and when all of the following conditions are satisfied:
the amount of turnover can be measured reliably;
it is probable that the company will receive the consideration; and
the costs incurred and the costs to complete the service can be measured reliably.

 
2.4

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.

The estimated useful lives range as follows:

Property improvements
-
5 years
Plant and machinery
-
4 years

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

4 -


 
LONDON HORMONE CLINIC LIMITED
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

2.Accounting policies (continued)

 
2.5

Debtors

Short-term debtors are measured at the transaction price, less any impairment. 

 
2.6

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.7

Financial instruments

The company only enters into basic financial instrument transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, loans from related parties.

Financial assets that are measured at cost and amortised cost are assessed at the end of each reporting period for objective evidence of impairment. If objective evidence of impairment is found, an impairment loss is recognised in the Profit and Loss Account.

Financial assets and liabilities are offset and the net amount reported in the Balance Sheet when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

 
2.8

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

 
2.9

Operating leases

Rentals paid under operating leases are charged to the Profit and Loss Account on a straight-line basis over the lease term.

 
2.10

Pensions

Defined contributions pension scheme

The company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the company pays fixed contributions into a separate entity. Once the contributions have been paid the company has no further payment obligations.

The contributions are recognised as an expense in profit or loss when they fall due. Amounts not paid are shown in accruals as a liability in the Balance Sheet. The assets of the plan are held separately from the company in independently administered funds.

5 -


 
LONDON HORMONE CLINIC LIMITED
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

2.Accounting policies (continued)

 
2.11

Current and deferred taxation

The tax expense for the year comprises current and deferred tax. Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the company operates and generates income.

Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the balance sheet date, except that:
The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and
Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met.

Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the balance sheet date.



3.


Employees

The average monthly number of employees, including directors, during the year was 10 (2023 - 8).

6 -


 
LONDON HORMONE CLINIC LIMITED
 
 

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

4.


Tangible fixed assets





Property improvements
Plant and machinery, etc
Total

£
£
£



Cost


At 1 January 2024
153,906
36,375
190,281


Additions
26,196
3,195
29,391



At 31 December 2024

180,102
39,570
219,672



Depreciation


At 1 January 2024
15,390
20,042
35,432


Charge for the year
36,604
6,160
42,764



At 31 December 2024

51,994
26,202
78,196



Net book value



At 31 December 2024
128,108
13,368
141,476



At 31 December 2023
138,516
16,333
154,849


5.


Debtors

2024
2023
£
£

Due after more than one year

Deferred tax asset
-
4,386


2024
2023
£
£

Trade debtors
40,371
21,313

Other debtors
80,977
70,551

Corporation tax repayable
-
6,504

121,348
98,368


7 -


 
LONDON HORMONE CLINIC LIMITED
 
 

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

6.


Creditors: amounts falling due within one year

2024
2023
£
£

Trade creditors
3,494
15,030

Other taxation and social security
136
536

Other creditors
285,550
210,616

289,180
226,182



7.


Commitments under operating leases

At 31 December 2024 commitments under non-cancellable operating leases totalled £315,000 (2023 - £382,500).


8.


Related party transactions

During the prior year amounts totalling £105,000 were advanced by the director. At the year end the amount due to the director was £60,670 (2023 - £103,458). The balance is unsecured, interest free and repayable on demand.

 
8 -